VIGL - vigilneuro.com Debt to Book Capitalization Ratio

Corporate company logo of Vigil Neuroscience Inc. (VIGL)

Vigil Neuroscience (VIGL) is accelerating drug discovery through robotic screening of brain cells. The dynamics of the debt-to-market capitalization ratio visualize the capital structure, where 0.31 determines the current value of the metric. Drug production relies on external CMO facilities in Europe and the US. Anticipation of the Phase II trial results for molecules targeting rare pathologies will serve as a key growth driver.

Vigil Neuro (VIGL) - Debts to Book Value from 07/04/2022 to 08/16/2025
Brand item of vigilneuro.com

The total liabilities-to-equity ratio measures the degree of financial leverage and the company's dependence on borrowed funds. This ratio determines the resilience of the balance sheet structure to market shocks. By analyzing the current correlation between debt and balance sheet capital, an investor assesses the risk of excessive leverage. For Vigil Neuroscience (VIGL), stability in raw material supplies reduces operational risks, strengthening the fundamental base. A low debt level confirms high capital autonomy.

Who Vigil Neuroscience competes with

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|Debts to Book Value Xenon Corp|Debt to Book Value Viking Therapeutics|Debt to Book Capitalization Ratio supernus.com|CPRX (Catalyst Pharmaceuticals, Inc.) - Debts to Book Capitalization|Debts to Net Assets Denali (DNLI)|HRMY (Harmony Pharma) - Debts to Book Capitalization|Debt to Net Assets Biohaven Corp BHVN|Debts to Book Capitalization AMLX (Amylyx Pharmaceuticals)|TRVI: Debts to Net Assets|Praxis Precision Medicines, Inc. (PRAX) - Debt to Book Capitalization Ratio|Debt to Book Capitalization Ratio Anavex|CBLL - Debt to Book Value|Debt to Net Assets Ratio PRTA|Debt to Book Capitalization Ratio Alector, Inc. ALEC|Debt to Book Value Ratio annexonbio.com (ANNX)|OMER: Debts to Book Capitalization|NGNE - Debts to Book Value|AC Immune Corp - Debt to Book Value|VYGR: Debts to Book Capitalization|Debt to Book Capitalization Ratio Neumora Therapeutics NMRA|SCLX (scilexholding.com) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio TVGN (Tevogen Bio)|Debts to Book Value ACOG|CGTX (Cognition Therapeutics) - Debt to Book Capitalization Ratio|Debts to Net Assets Inhibikase Pharma (IKT)|Cassava Sciences, Inc. - Debts to Book Capitalization|Debt to Book Value Assertio Holdings ASRT|Debts to Book Capitalization COYA (Coya)|VTGN - Debts to Net Assets|Debts to Book Capitalization OVID|ABOS (Acumen Pharmaceuticals, Inc) - Debts to Book Value|Debt to Book Capitalization Ratio CervoMed Inc. (CRVO)|Debt to Book Value Ratio Alterity Therapeutics Ltd|Debts to Book Capitalization CLNN (Clene Inc.)|Debt to Book Value pepgen.com (PEPG)|JUNS: Debts to Book Capitalization|RLMD - Debts to Book Value|ANVS - Debt to Book Value|GRCE - Debt to Book Capitalization Ratio|Firefly Neuroscience - Debts to Book Capitalization|Klotho Neurosciences (KLTO) - Debts to Net Assets|NeuroSense Therapeutics Ltd - Debts to Book Capitalization|Debt to Net Assets RVPH|Debt to Book Capitalization Ratio MetaVia Inc (MTVA)|Debt to Book Capitalization Ratio NRXS (neuraxis.com)|HSDT - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Passage Bio Inc. PASG|NEUP (Neuphoria) - Debts to Book Capitalization|Minerva (NERV) - Debts to Book Value|ATHA: Debt to Book Value|ADXN (addextherapeutics.com) - Debts to Book Capitalization|ALZN - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio CYCN|Protagenic Therapeutics - Debt to Book Capitalization Ratio|Debts to Book Value pasitheaclinics.com KTTA|Debt to Book Value Cortigent CRGT|Debt to Book Capitalization Ratio avenuetx.com ATXI|Debts to Book Capitalization BCLI (BrainStorm Cell Therapeutics)|CARA - Debts to Net Assets|Debts to Book Capitalization CHRO (Chromocell Therapeutics Corporation)|Eliem Therapeutics Inc. (ELYM) - Debt to Net Assets|ITCI: Debts to Book Capitalization|Debts to Net Assets LBPH|Debt to Book Capitalization Ratio Marinus Pharmaceuticals, Inc. (MRNS)|Debt to Book Capitalization Ratio NKGen Biotech Inc NKGN|Debt to Book Value NeuroBo|Sage Therapeutics Inc - Debt to Net Assets Ratio|Synaptogenix, Inc. (SNPX) - Debt to Book Capitalization Ratio|TRVN - Debt to Book Value Ratio|Debts to Book Capitalization WENA|Debts to Book Value Cerevel Therapeutics Inc